International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

Jennifer J. Mueller; Henrik Lajer; Berit Jul Mosgaard; Slim Bach Hamba; Philippe Morice; Sebastien Gouy; Yaser Hussein; Robert A. Soslow; Brooke A. Schlappe; Qin C. Zhou; Alexia Iasonos; Claus Høgdall; Alexandra Leary; Roisin E. O'Cearbhaill; Nadeem R. Abu-Rustum

doi:10.1097/IGC.0000000000001263

International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

Jennifer J. Mueller^*, Henrik Lajer, Berit Jul Mosgaard, Slim Bach Hamba, Philippe Morice, Sebastien Gouy, Yaser Hussein, Robert A. Soslow, Brooke A. Schlappe, Qin C. Zhou, Alexia Iasonos, Claus Høgdall, Alexandra Leary, Roisin E. O'Cearbhaill, Nadeem R. Abu-Rustum

^*Corresponding author for this work

Department of Clinical Medicine

8 Citations (Scopus)

Abstract

Objective We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes. Methods This was a retrospective review spanning 1976-2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed. Results Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy - 55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%-85%) for patients with stage I to II disease and 17% (95% CI, 8%-29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%-86%) for patients who underwent fertility-preserving surgery. Conclusions Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.

Original language	English
Journal	International Journal of Gynecological Cancer
Volume	28
Issue number	5
Pages (from-to)	915-924
Number of pages	10
ISSN	1048-891X
DOIs	https://doi.org/10.1097/IGC.0000000000001263
Publication status	Published - 2018

Keywords

Fertility preservation
Ovarian cancer
Primary mucinous ovarian cancer
Survival

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/IGC.0000000000001263

Cite this

Mueller, J. J., Lajer, H., Mosgaard, B. J., Bach Hamba, S., Morice, P., Gouy, S., Hussein, Y., Soslow, R. A., Schlappe, B. A., Zhou, Q. C., Iasonos, A., Høgdall, C., Leary, A., O'Cearbhaill, R. E., & Abu-Rustum, N. R. (2018). International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers. International Journal of Gynecological Cancer, 28(5), 915-924. https://doi.org/10.1097/IGC.0000000000001263

Mueller, JJ, Lajer, H, Mosgaard, BJ, Bach Hamba, S, Morice, P, Gouy, S, Hussein, Y, Soslow, RA, Schlappe, BA, Zhou, QC, Iasonos, A, Høgdall, C, Leary, A, O'Cearbhaill, RE & Abu-Rustum, NR 2018, 'International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers', International Journal of Gynecological Cancer, vol. 28, no. 5, pp. 915-924. https://doi.org/10.1097/IGC.0000000000001263

@article{e9a8505c35b64ae492ffb6870711a174,

title = "International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers",

abstract = "Objective We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes. Methods This was a retrospective review spanning 1976-2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed. Results Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy - 55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%-85%) for patients with stage I to II disease and 17% (95% CI, 8%-29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%-86%) for patients who underwent fertility-preserving surgery. Conclusions Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.",

keywords = "Fertility preservation, Ovarian cancer, Primary mucinous ovarian cancer, Survival",

author = "Mueller, {Jennifer J.} and Henrik Lajer and Mosgaard, {Berit Jul} and {Bach Hamba}, Slim and Philippe Morice and Sebastien Gouy and Yaser Hussein and Soslow, {Robert A.} and Schlappe, {Brooke A.} and Zhou, {Qin C.} and Alexia Iasonos and Claus H{\o}gdall and Alexandra Leary and O'Cearbhaill, {Roisin E.} and Abu-Rustum, {Nadeem R.}",

year = "2018",

doi = "10.1097/IGC.0000000000001263",

language = "English",

volume = "28",

pages = "915--924",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "Lippincott Williams & Wilkins, Ltd.",

number = "5",

}

TY - JOUR

T1 - International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

AU - Mueller, Jennifer J.

AU - Lajer, Henrik

AU - Mosgaard, Berit Jul

AU - Bach Hamba, Slim

AU - Morice, Philippe

AU - Gouy, Sebastien

AU - Hussein, Yaser

AU - Soslow, Robert A.

AU - Schlappe, Brooke A.

AU - Zhou, Qin C.

AU - Iasonos, Alexia

AU - Høgdall, Claus

AU - Leary, Alexandra

AU - O'Cearbhaill, Roisin E.

AU - Abu-Rustum, Nadeem R.

PY - 2018

Y1 - 2018

N2 - Objective We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes. Methods This was a retrospective review spanning 1976-2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed. Results Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy - 55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%-85%) for patients with stage I to II disease and 17% (95% CI, 8%-29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%-86%) for patients who underwent fertility-preserving surgery. Conclusions Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.

AB - Objective We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes. Methods This was a retrospective review spanning 1976-2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed. Results Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy - 55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%-85%) for patients with stage I to II disease and 17% (95% CI, 8%-29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%-86%) for patients who underwent fertility-preserving surgery. Conclusions Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.

KW - Fertility preservation

KW - Ovarian cancer

KW - Primary mucinous ovarian cancer

KW - Survival

U2 - 10.1097/IGC.0000000000001263

DO - 10.1097/IGC.0000000000001263

M3 - Journal article

C2 - 29561302

AN - SCOPUS:85047969394

SN - 1048-891X

VL - 28

SP - 915

EP - 924

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

IS - 5

ER -

International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this